ArticleInternational journal of clinical and experimental pathology2015
Down-regulation of miR-497 is associated with poor prognosis in renal cancer.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Prognostic Value of MicroRNA-497 in Various Cancers: A Systematic Review and Meta-Analysis.Disease markers · 2019Pooled it
- MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.Oncotarget · 2015Pooled it
- The role of natural products versus miRNA in renal cell carcinoma: implications for disease mechanisms and diagnostic markers.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Biomarkers in renal cell carcinoma and their targeted therapies: a review.Exploration of targeted anti-tumor therapy · 2023Review
- MiRNAs in renal cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Review
- MicroRNA Signature in Renal Cell Carcinoma.Frontiers in oncology · 2020Review
- Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma.Cancer cell international · 2020Article
- Identifying Key MicroRNAs Targeted by Narenmandula in a Rodent Nephropathy Model.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- MicroRNA-497-5p Induces Cell Cycle Arrest Of Cervical Cancer Cells In S Phase By Targeting CBX4.OncoTargets and therapy · 2019Article
- Clinical response and prognostic significance of serum miR-497 expression in colorectal cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- Molecular Mechanisms in Clear Cell Renal Cell Carcinoma: Role of miRNAs and Hypermethylated miRNA Genes in Crucial Oncogenic Pathways and Processes.Frontiers in genetics · 2019Review
- miRNA-mRNA Associated With Survival in Endometrial Cancer.Frontiers in genetics · 2019Article
- Fifteen-gene expression based model predicts the survival of clear cell renal cell carcinoma.Medicine · 2018Article
- Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer.Journal of translational medicine · 2018Article
- Article
- miR-497 inhibited proliferation, migration and invasion of thyroid papillary carcinoma cells by negatively regulating YAP1 expression.OncoTargets and therapy · 2018Article
- Prognostic Role of MicroRNA-497 In Cancer Patients: A Meta-analysis.Journal of Cancer · 2018Article
- miR-514a-3p functions as a tumor suppressor in renal cell carcinoma.Oncology letters · 2017Article
- MicroRNA‑497 inhibits cellular proliferation, migration and invasion of papillary thyroid cancer by directly targeting AKT3.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionClear cell renal cell carcinoma (ccRCC) is the most common type of cancer in the adult kidney, and the prognosis of metastatic ccRCC remains poor with high mortality. Recent study indicated that microRNAs (miRNAs) played critical roles in tumor progression. The aim of this study was to investigate the expression, biological role and clinical significance of miR-497 in ccRCC.
methodsQuantitative real-time PCR (qRT-PCR) was performed to detect the expression of miR-497 in renal cancer cell lines and ccRCC tissues. The association between miR-497 expression and overall survival was estimated by the Kaplan-Meier method. Gain of function assays were performed in the 786-O renal cancer cell line.
resultsExpression of the miR-497 was significantly decreased in renal cancer cell lines and ccRCC tissues when compared with normal human proximal tubule epithelial cells and adjacent non-tumor tissues. Decreased miR-497 expression was significantly associated with tumor stage, histological grade and lymph node metastases. Significantly shorter overall survival was observed in patients with lower expression of the miR-497. Overexpression of miR-497 significantly inhibited renal cancer cell proliferation, migration and invasion.
conclusionsOur results demonstrated that miR-497 was decreased in ccRCC tissues and may provide a potential prognostic biomarker and a potential target for therapeutic intervention.
Indexed as
Identifiers
25755771PMC4348935W50707998What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.